Keratoacanthoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The keratoacanthoma market size is expected to grow from USD 3.18 billion in 2025 to USD 3.38 billion in 2026 and is forecast to reach USD 4.57 billion by 2031 at 6.24% CAGR over 2026-2031. This report is segmented by Type (Solitary Keratoacanthoma, Multiple Keratoacanthoma, Giant Keratoacanthoma, and Others), Treatment and Diagnosis (Diagnostic Procedures, Therapeutic Procedures, and Pharmacological Treatment), End User (Hospitals, Dermatology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Keratoacanthoma Market Trends and Insights

Aging and Cumulative Ultraviolet Exposure

The keratoacanthoma market reflects the growing number of older people with long-term exposure to ultraviolet radiation. The reported global peak age for keratoacanthoma has shifted to 65 to 71 years, from 50 to 69 years during the 1990s. Age can weaken nucleotide excision repair, base excision repair, and Langerhans cell surveillance, which leaves repeatedly sun-damaged skin more susceptible to squamoproliferative changes. The World Health Organization reported an 88% increase in deaths from occupational solar ultraviolet exposure-related non-melanoma skin cancer between 2000 and 2019. Australia, New Zealand, and the United States have particularly high age-standardized non-melanoma skin cancer incidence, which supports sustained demand for assessment and treatment. In Southeast Asia and the Middle East, substantial outdoor exposure and historically limited surveillance can lead to a larger visible caseload as diagnostic capacity improves.

Screening, Referral, and Non-Surgical Care Expansion

The keratoacanthoma market benefits when skin-lesion screening and early specialist referral identify lesions before they become more complex to manage. Community dermatologists and trained nurse practitioners can use digital imaging to route patients with suspicious lesions to specialists, which can shorten the time to diagnosis. The same referral model can help patients with multiple, eruptive, or cosmetically sensitive lesions access care that does not rely solely on excision. Intralesional methotrexate has produced clearance in 70% to 92% of cases across retrospective series, while intralesional 5-fluorouracil has achieved resolution within 3 weeks at 3 injection intervals. Radiation treatment and X-ray therapy remain relevant for older or immunocompromised patients with substantial wound-healing risk. Cryotherapy, which has shown resolution rates of 87%, can provide a lower-cost option in settings with fewer specialist resources.

Diagnostic Ambiguity and Regulatory Pathways

The keratoacanthoma market remains limited by the clinical and histological overlap between keratoacanthoma and well-differentiated cutaneous squamous cell carcinoma. This uncertainty encourages treatment that prioritizes complete excision and histopathologic confirmation, even when a lesion may otherwise be considered for conservative care. In the 2024 Mohs analysis, 0.8% of lesions initially managed as keratoacanthoma were upstaged during surgery to moderate or poorly differentiated cutaneous squamous cell carcinoma. Coding cases as cutaneous squamous cell carcinoma to obtain reimbursement can understate the condition-specific treatment opportunity in billing data. The same lack of clear coding and distinct clinical pathways weakens the outcome data needed for a keratoacanthoma-specific drug indication. Without an established regulatory pathway, investment in targeted drug development remains less attractive than investment in the clearer cutaneous squamous cell carcinoma indication.

Other drivers and restraints analyzed in the detailed report include:

• Growth of Tissue-Sparing Mohs Micrographic Surgery
• AI-Assisted Dermoscopy and Therapy-Associated Lesions
• Evidence, Access, and Reimbursement Constraints

Segment Analysis

Solitary keratoacanthoma held 60.34% of the Keratoacanthoma market size in 2025, reflecting the predominance of the classic single-lesion presentation. This presentation is a rapidly growing, dome-shaped nodule with a central keratin-filled crater that commonly arises on chronically sun-exposed skin. Incidence now peaks among people aged 65 to 71 years, which aligns with ultraviolet-driven disease in older, fair-skinned populations. A single resectable lesion usually follows a direct route to excision or Mohs surgery with less diagnostic complexity. Giant keratoacanthoma, defined as a lesion larger than 2 cm, can require multistage reconstruction or radiation because local tissue destruction, challenging locations, and wound-healing risk can make primary excision insufficient.

Multiple keratoacanthoma is forecast to grow at a 6.65% CAGR through 2031, supported by therapy-associated eruptive cases at the oncology and dermatology interface. BRAF inhibitor monotherapy has been associated with keratoacanthoma in 8.97% of patients, compared with 1.82% for BRAF plus MEK inhibitor combinations. A 2025 review of 172 drug-induced eruptive keratoacanthoma and squamous cell carcinoma cases found that immune checkpoint inhibitor-associated lesions more often affected older people and the lower extremities. These cases are more often treated with oral retinoids and intralesional corticosteroids than excision, creating a different treatment revenue profile from solitary lesions. Ferguson-Smith syndrome, Grzybowski generalized eruptive keratoacanthoma, subungual keratoacanthoma, and mucosal keratoacanthoma are rare forms where lesion multiplicity, recurrence, or tissue anatomy can complicate long-term surgical care.

Therapeutic procedures held 56.38% of the treatment and diagnosis segment in 2025. Surgical procedures support this position because excision combines treatment with definitive histopathologic staging. Mohs surgery is particularly relevant in cosmetically sensitive locations and cleared keratoacanthoma in a mean of 1.3 stages in the 2024 comparative study. Cryotherapy, electrodesiccation, curettage, and photodynamic therapy offer office-based local control when speed is more important than histopathologic confirmation. Cryotherapy had resolution rates of 87% in the supplied clinical evidence base. Radiation remains important for older patients or medically complex patients who cannot undergo surgery, while diagnostic procedures such as dermoscopy and biopsy feed therapeutic volumes.

The Keratoacanthoma market size for pharmacological treatment is forecast to grow at a 7.13% CAGR through 2031. This path serves patients whose multiple or therapy-associated lesions would make surgery disproportionately burdensome. Intralesional methotrexate showed 70-92% clearance in retrospective series, while intralesional 5-fluorouracil resolved lesions in 3 weeks across 3 injection cycles. In July 2026, SKNV secured exclusive rights to a Washington University fluorouracil and calcipotriene patent portfolio for Kefunova Cream. The International Immunosuppression and Transplant Skin Cancer Collaborative had recommended the combination in April 2026 for high-risk patients, including organ transplant recipients. Oral retinoids and corticosteroids also have a distinct role in immune checkpoint inhibitor and BRAF inhibitor-associated eruptive disease.

Complete Report Scope:

• By Type
  • Solitary Keratoacanthoma
  • Multiple Keratoacanthoma
  • Giant Keratoacanthoma
  • Others
• By Treatment and Diagnosis
  • Diagnostic Procedures
    • Clinical Examination
    • Dermoscopy
    • Skin Biopsy & Histopathological Examination
    • Others
  • Therapeutic Procedures
    • Surgical Procedures
    • Destructive/Local Procedures
    • Radiation Therapy
    • Others
  • Pharmacological Treatment
    • Topical Treatments
    • Intralesional Treatments
    • Systemic Treatments
    • Others
• By End User
  • Hospitals
  • Dermatology Clinics
  • Ambulatory Surgical Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 37.83% of the keratoacanthoma market size in 2025, supported by a high density of board-certified dermatologists and Mohs surgeons. The region also has established reimbursement for lesion excision and substantial use of checkpoint inhibitors and BRAF inhibitors. The United States accounted for most regional revenue, while Canada and Mexico contributed smaller but growing volumes. Canadian provincial health systems are expanding telemedicine dermatology referrals that can route previously undetected lesions into specialist care. The American Academy of Dermatology challenged the 2.8% Medicare physician fee cut that took effect in January 2025, which indicates continued pressure on provider access. Despite this pressure, established Mohs capacity and broader artificial intelligence-assisted dermoscopy support the region’s position.

Asia-Pacific is forecast to achieve the fastest regional growth at a 8.24% CAGR through 2031. Australia and New Zealand have high age-standardized non-melanoma skin cancer incidence, supporting a sizable base for skin lesion procedures and private insurance-backed excision. China and India are expanding Mohs capacity in urban hospital dermatology departments, although rural access gaps remain. Government dermatology training programs in both countries can expand the specialist workforce needed to address latent demand. Japan’s population was more than 28% aged 65 or older, which aligns with growing clinical documentation of keratoacanthoma in older adults. South Korea’s digital health infrastructure supports faster deployment of artificial intelligence-enabled dermoscopy and may make it an early setting for new triage tools.

Europe held a significant keratoacanthoma market share in 2025, led by Germany, the United Kingdom, and France with integrated dermatology and histopathology services. The European Academy of Dermatology and Venereology is supporting Mohs accreditation expansion across member states, addressing a long-standing capacity gap with North America. Spanish clinical literature has documented intralesional methotrexate and 5-fluorouracil as treatment alternatives for facial and acral lesions in older patients. The Middle East and Africa remain at an earlier stage, with Gulf Cooperation Council countries advancing through private hospital growth and medical tourism. Brazil anchors South American demand through its urban hospital network, elevated ultraviolet exposure, and increasing immuno-oncology prescribing.

List of Companies Covered in this Report:

• Almirall
• Amgen
• AstraZeneca
• Bausch Health
• Bayer
• Biofrontera
• Bristol-Myers Squibb
• Carl Zeiss
• Castle Biosciences, Inc.
• Cipla
• DermTech, Inc.
• Eli Lilly and Company
• Galderma Group AG
• GE HealthCare Technologies Inc.
• GLENMARK PHARMACEUTICALS LTD
• Danaher
• Leo Pharma
• Merck
• Novartis
• Pfizer
• Sanofi
• Sun Pharmaceuticals Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support